Efficacy and Tolerance of Interferon-α in Hypereosinophilic Syndromes. a Retrospective Multicenter Study on 29 Patients

Pauline De Malglaive,Matthieu Groh,Guillaume Lefèvre, Chafika Morati Hafsaoui,Magda Alexis,Mathilde Hunault,Julien Seneschal, Hilaire Charlanne,Claude Preudhomme,Bernard Bonnotte,Jean Emmanuel Kahn

Blood（2019）

引用 0|浏览2

暂无评分

摘要

Background: Corticosteroids and imatinib are the first line treatment in hypereosinophilic syndromes (HES) according FIP1L1-PDGFRA (F/P) positivity. In HES unrelated to F/P, second line available treatment are historically interferon alpha (IFN-α) and hydroxyurea, while anti-interleukin-5 antibodies are currently investigated. Data concerning efficacy of IFN-αin HES are limited to small case series and one large international study with a short-term follow-up.

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要